We further evaluated the clinical significance of the variation in KRAS G12/G13 MAF in cfDNA in a subset of 14 NSCLC patients receiving systemic first-line therapy at two subsequent time points, at the time of treatment evaluation (T1) and on disease progression (T2). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.